Several new therapies are reshaping diabetes care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted leading choices. Retatrutide, a dual GIP and GLP-1 site stimulant, demonstrates substantial weight loss and improved glucose levels. Cagrillintide, one GLP-1 activato